A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer

Published:2009-05 Issue:2 Volume:113 Page:205-209
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Argenta Peter A.,Thomas Sajeena G.,Judson Patricia L.,Downs Levi S.,Geller Melissa A.,Carson Linda F.,Jonson Amy L.,Ghebre Rahel

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference36 articles.

1. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N. Engl. J. Med.,2006

2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N. Engl. J. Med.,1996

3. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results;Piccart;J. Natl. Cancer Inst.,2000

4. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial;Fisher;J. Clin. Oncol.,1986

5. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial;Untch;Ann. Oncol.,2008

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear receptors in ovarian cancer: changing paradigms in cancer therapeutics;Frontiers in Oncology;2024-07-15

2. The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer;Cancer Letters;2024-07

3. Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature;The Oncologist;2024-05-20

4. An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study);International Journal of Gynecologic Cancer;2024-05-09

5. Systemische Therapie der epithelialen serösen Ovarialkarzinome;Deutsche Zeitschrift für Onkologie;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3